The authors have no conflict of interest to declare.
Age-related macular degeneration—clinical review and genetics update
Article first published online: 9 JUL 2013
Published 2013. This article is a U.S. Government work and is in the public domain in the USA.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Volume 84, Issue 2, pages 160–166, August 2013
How to Cite
Age-related macular degeneration—clinical review and genetics update., .
- Issue published online: 9 JUL 2013
- Article first published online: 9 JUL 2013
- Accepted manuscript online: 28 MAY 2013 01:01PM EST
- Manuscript Revised: 23 MAY 2013
- Manuscript Accepted: 23 MAY 2013
- Manuscript Received: 19 APR 2013
- age-related macular degeneration;
- disease management;
- rare-variant association;
- risk prediction;
- whole-exome sequencing;
- whole-genome sequencing
Age-related macular degeneration (AMD) is the leading cause of central vision impairment in persons over the age of 50 years in developed countries. Both genetic and non-genetic (environmental) factors play major roles in AMD etiology, and multiple gene variants and lifestyle factors such as smoking have been associated with the disease. While dissecting the basic etiology of the disease remains a major challenge, current genetic knowledge has provided opportunities for improved risk assessment, molecular diagnosis and clinical testing of genetic variants in AMD treatment and management. This review addresses the potential of translating the wealth of genetic findings for improved risk prediction and therapeutic intervention in AMD patients. Finally, we discuss the recent advancement in genetics and genomics and the future prospective of personalized medicine in AMD patients.